- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
April 15, 2022
From Benzinga
From Benzinga
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers
April 14, 2022
From Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
April 13, 2022
From Benzinga
From Benzinga
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
April 11, 2022
From Benzinga
From InvestorPlace
From Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
April 04, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
March 25, 2022
From Benzinga
Why Are ImmunoGen Shares Trading Lower Today
March 21, 2022
From Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
From Benzinga
2 Top Stocks to Buy in March and Hold Forever
March 15, 2022
From Motley Fool
The OTCQX's Top 10 Experience A Shuffle In February
March 15, 2022
From Benzinga
From Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Motley Fool
Viatris Just Snagged a Major FDA Approval
March 03, 2022
From Motley Fool
2 Biotech Stocks That Could Make You Richer
March 02, 2022
From Motley Fool
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
From Benzinga
From Benzinga
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
February 16, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.